An approach to estimating the intangible costs of multiple sclerosis according to disability in Catalonia, Spain

Multiple Sclerosis

Volumn 13, Issue 6, 2007, Pages 800-804

  Casado, V ^a   Romero, L ^a   Gubieras, L ^a   Alonso, L ^a   Moral, E ^a   Martinez Yelamos S ^a   Martinez Yelamos A ^b   Carmona, O ^c   Arbizu, T ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Hospital de San Lorenzo   (Spain)

^c HOSPITAL DE FIGUERES   (Spain)

Author keywords

Disability evaluation; Expanded Disability Status Scale (EDSS); Intangible costs; Multiple sclerosis; Quality of life; Quality adjusted life years

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST OF ILLNESS; DISABILITY SEVERITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HEALTH ECONOMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REFERENCE VALUE; SENSITIVITY ANALYSIS; SOCIAL DISABILITY; VISUAL ANALOG SCALE;

ADULT; AGE OF ONSET; COST OF ILLNESS; DISABILITY EVALUATION; FEMALE; HUMANS; MALE; MULTIPLE SCLEROSIS; SPAIN;

EID: 34447549105     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458506073480     Document Type: Article

References (18)

1. Weinshenker BG, Bass B, Rice GPA. The natural history of multiple sclerosis: a geographically based study. Brain 1989; 112: 133-46.
2. Bufill E, Blesa R, Galan I, Dean G. Prevalence of multiple sclerosis in the region of Osona, Catalonia, Northern Spain. J Neurol Neurosurg Psychiatry 1995; 58: 577-81.
3. Kobelt G, Pugliatti M. Cost of multiple sclerosis in Europe. Eur J Neurol 2005; 12: 63-67.
4. Patwardhan MD, Matchar DB, Samsa GP, McCoy DC, Williams RG, Li TT. Costs of multiple sclerosis by level of disability: a review of literature. Mult Scler 2005; 11: 232-39.
5. Fisk JD, Brown MG, Sketris IS, Metz LM, Murray TJ, Stadnyk KJ. A comparison of health utility measures for the evaluation of multiple sclerosis treatments. J Neurol Neurosurg Psychiatry 2005; 76: 58-63.
6. Havranek E, Simon TA, L'Italien G, Smitten A, Hamber AB, Chen R et al. The relationship between health perception and utility in heart failure patients in a clinical trial: results from an OVERTURE substudy. J Card Fail 2004; 10: 339-43.
7. Mrus JM, Yi MS, Freedburg KA, Wu AW, Zachin R, Gorshi H et al. Utilities derived from visual analog scale in patients with HIV/ AIDS. Med Decis Making 2003; 23: 414-21.
8. Naglie G, Tomlinson G, Tansey C, Irvine J, Ritvo P, Black SE et al. Utility-based quality of life measures in Alzheimer disease. Qual Life Res 2006; 15: 631-43.
9. Torrance GW, Feeny D, Furlong W. Visual analog scales: do they have a role in the measurement of preferences for health states? Med Decis Making 2001; 21: 239-34.
10. The Canadian Burden of Illness Study Group. Burden of multiple sclerosis: part II: quality of life. Can J Neurol Sci 1998; 25: 31-38.
11. Grima DT, Torrance GW, Francis G, Rice G, Rosner AJ, Lafortune L. Cost and health related quality of life consequences of multiple sclerosis. Mult Scler 2000; 6: 91-98.
12. Kobelt G, Lindgren P, Parhin D, Francis D, Johnson M, Bates D et al. Costs and quality of life in multiple sclerosis. A cross-sectional study in the United Kingdom. EFI Research Report No. 398, 2000.
13. Kobelt G, Lindgren P, Smala A, Jönson B. Costs and quality of life in multiple sclerosis. An observational study in Germany. HEPAC 2001; 2: 60-68.
14. Kobelt G, Berg J, Atherley D, Hadjimichael O, Jönson B. Costs an quality or life in multiple sclerosis, a cross-sectional study in the USA. SSE/EFI Working Paper Series in Economics and Finance No. 594, December 2004: 2-34.
15. Henriksson F, Fredrikson S, Masterman T, Jönson B. Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden. Eur J Neurol 2001; 8: 27-35.
16. Newhouse JP. US and UK health economics: two disciplines separated by a common language? Health Econ 1998; 7: S79-92.
17. Torrance GW, Feeny DH, Furlong WJ, Barr RD, Zhang Y, Wang Q. Multiattribute utility function for a comprehensive health status classification system. Health Utility Mark 2. Med Care 1996; 34: 702-22.
18. Gyrd-Hansen. Willingness to pay for a QALY, theoretical and methodological issues. Pharmacoeconomics 2005; 23: 423-32.